Targeting KRAS: Crossroads of Signaling and Immune Inhibition
Mutations of RAS are commonly seen in human cancers, especially in lung, colorectal, and pancreatic adenocarcinoma. Despite huge effort for decades, targeting RAS mutations has been ‘‘undruggable’’ because of the molecular instability of RAS protein inhibition. However, the recent discovery of the K...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Innovative Healthcare Institute
2022-08-01
|
| Series: | Journal of Immunotherapy and Precision Oncology |
| Subjects: | |
| Online Access: | https://theijpt.org/doi/pdf/10.36401/JIPO-22-5 |